| Open Document File Size: 14,07 KBShare Result on Facebook
City TARRYTOWN / New York / PARIS / / Company BioMarin Pharmaceutical Inc. / AMF / Regeneron Pharmaceuticals Inc. / Regeneron Ireland / Sanofi / BioMarin GALNS Ltd. / Genzyme / / Country United States / / Currency USD / / / Event Company Listing Change / / IndustryTerm biopharmaceutical / therapeutic solutions / consumer healthcare / science-based biopharmaceutical / healthcare / diabetes solutions / / MedicalCondition atopic dermatitis / colorectal cancer / diabetes / rare pediatric disease / rare inflammatory condition / hypercholesterolemia / rheumatoid arthritis / eye diseases / asthma / rare pediatric diseases / / Organization PCSK9 Development & Launch Unit / U.S. Food and Drug Administration / European Union / U.S. Securities and Exchange Commission / / Person Manisha Narasimhan / Sebastien Martel / Ned Braunstein / Hala Mirza / Jack Cox / / / Position integrated global healthcare leader / Vice President / Regulatory Affairs / Private / / ProvinceOrState New York / / Technology therapeutic solutions / / URL www.regeneron.com / /
SocialTag |
July 30, 2014 Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)